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ABSTRACT
A simple pharmacokinetic model and a specially designed
dermal vapor exposure chamber which provides
respiratory protection were used to determine the rate of
penetration of hydrazine and 1,1-dimethylhydrazine
(UDMH) vapor through the skin of rats. Parameters for
the pharmacokinetic model were determined from
intravenous and inhalation exposure data. The model was
then used to estimate the skin permeation coefficient for
hydrazine or UDMH vapor from the dermal-vapor
exposure data. This analysis indicates that UDMI-I vapor
has a relatively high permeability through skin (0.7
cm/hr), a value somewhat higher than was obtained for
hydrazine by the same procedure (0.09 cm/hr). Based on
these skin permeability results, a skin-only vapor exposure
limit giving protection equivalent to the inhalation
Threshold Limit Value (TLV) could be calculated. The
current TLV's for UDMH and hydrazine are 0.5 and 0.1
ppm, respectively. The corresponding skin-only TLV
equivalents, for personnel wearing respiratory protection,
are 32 ppm for UDMH and 48 ppm for hydrazine.
Should the proposed lowering of the TLV's for these
compounds to 0.01 ppm be adopted, the equivalent
skin-only TLV's would become 0.64 ppm for UDMH and
4.8 ppm for hydrazine.
INTRODUCTION
Aerozine-50, a 50:50 by weight blend of UDMH and
hydrazine, is an important fuel used in the Titan series
missile. UDMH and hydrazine are caustic liquids which
produce severe chemical burns. Therefore, personnel
working with these fuels must wear protective clothing
suitable to prevent liquid contact with the skin or eyes.
In addition, inhalation of the fuel vapors has been shown
to produce both acute and chronic toxicity, including
carcinogenicity I. As a result, the American Conference
of Government Industrial Hygienists (ACGIH) currently
recommends TLVs of 0.1 ppm for hydrazine and 0.5 ppm
for UDMH, and is considering lowering the TLVs for
both chemicals to 0.01 ppm _. Thus respiratory protection
is also necessary whenever significant concentrations of
vapor may be present.
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Because of uncertainty concerning the significance of
dermal exposure to fuel vapor, it has often been the
practice in the past to require that personnel working with
these fuels wear a cumbersome, self-contained ensemble
to provide full-body protection against vapor. This
self-contained ensemble seriously degrades performance,
so there is interest in establishing when protection of the
skin from fuel vapors is needed, and when inhalation
protection and prevention of liquid contact will suffice.
Other than direct irritation of the skin, which occurs at
levels well above the TLV, the principal issue concerning
dermal exposure to fuel vapor is the potential for systemic
toxicity due to penetration of vapor through the skin as
compared to inhalation. The purpose of the current study
was to estimate a dermal equivalent of the permissible
hydrazine inhalation exposure level in order to establish
realistic guidelines for ensuring the personal safety of
individuals potentially exposed to hydrazine or UDMH
vapors.
METHODS
Details of the experimental methods have been reported
previously 3,_, so only a brief description is provided here.
For the dermal vapor exposures, rats were exposed to
hydrazine or UDMH vapors in a specially designed
chamber 3 which provided respiratory protection by the use
of masks, but allowed exposure of the whole body, which
had been closely clipped of fur, to the chamber
atmosphere. The same chamber was used for the
inhalation exposures, but the use of masks was omitted
and the fur was not clipped. Male Fischer 344 rats (200
to 280 g) were trained to wear a harness and, for the
dermal exposures, latex face mask prior to the exposures.
Twenty-four hours before the exposure, jugular cannulas
were surgically implanted and exteriorized at the back of
the neck. Just prior to the exposure, six rats were placed
in the chamber and the cannulas were routed outside the
chamber for blood collection during the exposure. For
intravenous exposures, hydrazine or UDMH was
introduced in a saline vehicle. Blood samples were drawn
through a jugular cannula at 0.5, 1, 2, and 4 hours after
injection. Analysis of blood samples involved
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derivitizationwith chlorobenzaldehyde3 or acetone 4,
followed by gas chromatography.
A relatively simple one-compartment open
pharmacokinetic model was used to relate the measured
blood concentrations during exposure to the total amount
of chemical (hydrazine or UDMH) in the animal and the
total amount metabolized. Two processes were
incorporated in the model: slowly reversible chemical
reaction with components of the blood and tissues, and
irreversible clearance of free chemical by a saturable
process. Incorporation of these two processes into the
model was necessary to provide a coherent description of
all of the data from the three exposure routes. The total
amount of unreacted chemical in the animal (Afree) at a
given time is determined by integrating the following
equation with initial condition Afree = 0, for the vapor
exposures, or Afree = dose (rag), for the intravenous
exposures:
dAfree/dt = Rskin + Rinh - Rx - Rclear
where:
Rskin = rate of penetration through skin
= P * A * Cdermal
Rinh = rate of inhalation
= Qalv *CinhaI
Rx = rate of reaction
=Kr*Cfree*Vd-Kd*Ax
Rclear = rate of clearance
= Vmax * Cfree / (Kin + Cfree)
In these equations, P is the skin permeation coefficient
(cm/hr), A is the skin area (cm_), Cdermal is the chamber
concentration for the dermal vapor exposures (mg/ml),
Qalv is the alveolar ventilation rate (L/hr), Cinhal is the
chamber concentration for the inhalation exposures
(rag/L), Cfree is the concentration of unreacted chemical
in the blood (mg/L), Kr is the rate constant for reaction
with blood and tissue components (/hr), Vd is the volume
of distribution in the animal (L), Kd is the rate constant
for reversal of the reaction with blood or tissue (/hr), Ax
is the amount of reacted chemical (mg), Vmax is the
maximum clearance rate for free chemicaI (mg/hr), and
Km is the Michaelis-Menton constant for the clearance
process (rag/L). Two major assumptions of the model are
that the rate constants for reaction are the same in blood
and tissues, and that the hydrazone derivative procedure
effectively reverses the reaction with blood components so
that the measured concentration is the sum of free and
reacted chemical:
Cmeasured = Cfree + Ax/Vd
Qalv and A were calculated on the basis of empirically
derived relationships to body weight, with typical values
of about 6.7 L/hr and 260 cm 2, respectively. The volume
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of distribution was set to total body water (65% of body
weight). The kinetic constants Kr, Kd, Vmax, and Km
were established by iterative fitting of the inhalation and
intravenous exposure data sets. Although these
parameters are highly correlated, their affects on the
behavior of the model were sufficiently distinct to
estimate each of the parameters relatively independently.
The final step was to estimate P from fitting the dermal
vapor exposure data. The numerical integration and
non-linear parameter estimation was performed with
SIMUSOLV (Mitchell and Gauthier Associates, Inc.,
Concord MA) on a VAX 8530.
RESULTS
The model was able to provide a reasonably good
representation of the intravenous and inhalation data for
UDMH (Figs. 1 and 2) using Parameter values of
Kr = 1 i/hr, Kd = 1.9/hr, Vmax = 8.7 mg/hr, and Km =0.6
mg/L Althougffthe model somewhat overestimates the
blood concentrations at early times in the inhalation
exposure, it predicts the Correct steady-state behavior and
performs remarkably well at describing the complex
intravenous kinetics. The value of the skin permeation
coefficient that yielded the best agreement between the
model and the dermal vapor exposure data was 0.7 cm/hr
(Fig. 3).
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Figure 1. Model-Predicted (curves) and Experimental
(symbols) Blood Concentrations of UDMH for
Intravenous Doses of 24 mg/kg (upper curve, solid
symbols) and 12 mg/kg (lower curve, open symbols).
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Figure 2. Model-Predicted and Experimental Blood
Concentrations of UDMH for Inhalation Exposures at 108
ppm (upper cuiv% solid symbols), 104 ppm (middle
curve, crossed symbols) and 95 ppm (lower curve, open
symbols).
Figure 4. Model-Predicted and Experimental Blood
Concentrations of Hydrazine for Intravenous Doses of 12
mg/kg (upper curve, solid symbols) and 6 mg/kg (lower
curve, open symbols).
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Figure 3. Model-Predicted and Experimental Blood
Concentrations of UDMH for Skin-Only Vapor Exposures
at 1028 ppm (upper curve, solid symbols) and 895 ppm
of UDMH vapor (lower curve, open symbols).
Figure 5. Model-Predicted and Experimental Blood
Concentrations of Hydrazine for Inhalation Exposures at
10.7 ppm (upper curve, solid symbols) and 9.3 ppm
(lower curve, open symbols).
An earlier analysis for hydrazine s obtained a value of 0.06
cmlhr, but that analysis used a very different
pharmacokinetic model. To assess the impact of the
change of model, the model described above was used to
re-evaluate the hydrazine data. The new model was able
to provide a general description of the hydrazine data as
well (Figs. 4 and 5), using parameter values of Kr=.031,
Kd=.055, Vmax=3.1, and Km=50. The only other
change required was to restrict the volume of distribution
to the blood volume (5 % of body weight). The value of
P determined with the new model was 0.092 (Fig. 6), in
good agreement with the earlier value.
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Figure 6. Model-Predicted and Experimental Blood
Concentrations of Hydrazine for Skin-Only Vapor
Exposures at 486 ppm (upper curve, solid symbols), 476
ppm (middle curve, crossed symbol), and 105 ppm (lower
curve, open symbols).
Once we have established the skin permeation
coefficients, we can calculate the relative importance of
the dermal and inhalation routes of exposure for systemic
toxicity. Assuming that the rat is a good model for skin
absorption in the human, a measure of the rate of uptake
of chemical through the skin is simply P'A, where A is
the exposed skin area for humans, generally taken to be
2 m2. The equivalent measure of uptake for inhalation is
just Qp, which is commonly taken to be 800 L!hr. The
ratio of inhalation to dermal uptake is then Qp/(P*A).
Applying this formula to UDMH, the ratio of inhalation
to dermal uptak e is then 64, and the similar ratio for
hydrazine, using P=0.09, is 487. Multiplying these
ratios by the current TLVs, we obtain estimates for the
equivalent skin-only exposure levels of 32 ppm for
UDMH and 48 ppm for hydrazine. At the proposed
TLVs of 0.01 ppm, the skin-only equivalents would be
0.64 ppm and 4.8 ppm, respectively.
DISCUSSION
The approach described above for estimating safe
skin-only vapor exposure levels r¢!ies on a number of
assumptions. The principal assumption is that skin
permeation coefficients measured in rats are representative
of human skin values. While there is some evidence that
human skin is at least as good a barrier to chemical
vapors as rat skin 6, the exact relationship has not yet been
established for water soluble chemicals. The adequacy of
the rat as a model for skin absorption in humans is
therefore an important source of uncertainty which should
be considered in deriving human exposure guidelines.
Another key assumption in this approach is that the skin
and lungs act only as routes of entry for a chemical whose
effects are systemic. The method would be inappropriate
for a chemical which had direct effects either on the skin
or in the lungs at the concentrations of interest. In the
case of hydrazine and UDMH there are no significant
contact site effects at the level of the TLV.
Given the assumptions discussed above, this same
approach can be generally applied to other toxic
chemicals. Provided that skin permeation coefficients for
the vapor are either known or can be determined, the
calculation of the skin-only equivalent to a given
inhalation exposure guideline is straightforward. This
approach could provide a method for use by ACGIH or
OSHA in assigning quantitative skin notations. A similar
approach can also be used to determine appropriate
personal protection for potential short-term exposures as
a part of emergency response planning 7.
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